Harmony Biosciences
Manufacturing · Pennsylvania, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
630 W Germantown Pike Ste 215, Plymouth ...Phone Number
(484) 539-9800Website
www.harmonybiosciences.comRevenue
$959.9 MillionStock Symbol
HRMYIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Harmony Biosciences
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Explore more
Harmony Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Harmony Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Harmony Biosciences has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Harmony Biosciences launches new products
Harmony Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Harmony Biosciences had a recent Job posting/layoffs
Check out if Harmony Biosciences is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Harmony Biosciences has new funding data
Earning: See what the market has to say on Harmony Biosciences recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Harmony Biosciences
Recommended Actions
Reach out to Masked Content who joined Harmony Biosciences as Masked Content
Find more new buyers
Compare Similar Companies to Harmony Biosciences
Compare insights from companies similar to Harmony Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Harmony Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Harmony Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Harmony Biosciences.
Harmony Biosciences financials insights
Gather financial insights about Harmony Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Other Financing Round
$270M
2019
Unspecified
$200M
2020
Debt
$200M
Stock Offering
$128M
Harmony Biosciences Tech Stack
A closer look at the technologies used by Harmony Biosciences
See more technologies
Most Recent Scoops
Project
Harmony Biosciences has reported that the BP205 single ascending dose study demonstrated a favorable safety and tolerability profile, with no cardiovascular, hepatic, or visual disturbances observed, and adverse events limited to headache in approximately 10%, fatigue in approximately 4%, and diarrhea in approximately 3% of the healthy volunteer population.
Pharmaceuticals, Clinical Operations
Project
Harmony Biosciences has reported that Clemizole hydrochloride demonstrated a favorable safety and tolerability profile, requiring no echocardiogram or liver function test monitoring, with diarrhea reported in approximately 2% of patients, and an additional data cut is planned for presentation at the AES meeting later this year.
Pharmaceuticals, Clinical Operations
Project
Harmony Biosciences has completed dosing in the BP205 multiple ascending dose study, reporting target engagement adverse events of insomnia and polyuria, with insomnia characterized as neither severe nor sustained, and the full dataset including pharmacokinetic analysis expected to be disclosed in the fourth quarter.
Pharmaceuticals, Clinical Operations
Project
Harmony Biosciences has announced plans to aggressively develop BP205 and build a broad portfolio of Orexin-1 agonists in collaboration with partner Bioprojet, including the potential identification of follow-on compounds targeting narcolepsy, idiopathic hypersomnia, and broader CNS indications.
Partnership, Product Development, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
Harmony Biosciences News & Media
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 BillionHarmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 4, 2026, at 8:30 a.m. ET to discuss the results.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Harmony Biosciences
Sign Up For FreeTo access detailed company insights
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult... Read More
